Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR

Bone Marrow Transplantation
M MizutaniA Takami

Abstract

Although allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor (MSD) is a potentially curative post-remission treatment for adults with acute myeloid leukemia (AML) in their first CR, transplant-related morbidity and mortality remains a major drawback. We retrospectively compared the outcomes of patients who underwent autologous peripheral blood stem cell transplantation (auto-PBSCT; n=375) with those who underwent allogeneic bone marrow transplantation (allo-BMT; n=521) and allo-PBSCT (n=380) from MSDs for adults with AML/CR1, in which propensity score models were used to adjust selection biases among patients, primary physicians and institutions to overcome ambiguity in the patients' background information. Both the multivariate analysis and propensity score models indicated that the leukemia-free survival rate of auto-PBSCT was not significantly different from that of allo-BMT (hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.92 to 1.66; P=0.16) and allo-PBSCT (HR, 1.13; 95% CI, 0.85-1.51; P=0.40). The current results suggest that auto-PBSCT remains a promising alternative treatment for patients with AML/CR1 in the absence of an available MSD.

References

Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S SteinS J Forman
Dec 24, 1997·Bone Marrow Transplantation·H GondoY Niho
Aug 24, 1999·American Journal of Epidemiology·M M Joffe, P R Rosenbaum
Mar 9, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·C A LinkerJ L Wolfe
Jan 8, 2004·Journal of the National Cancer Institute·Paul C NathanJoseph Beyene
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
Jun 15, 2007·Bone Marrow Transplantation·L ScruccaF Aversa
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jul 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MaurilloAdriano Venditti
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hideki NakasoneKensuke Usuki
Feb 11, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Sergio GiraltBrenda Sandmaier
Jul 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert-Claude GorinUNKNOWN Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation
Dec 15, 2011·Blood·Christoph SchmidUNKNOWN Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Dec 27, 2011·The Lancet Oncology·Markus PfirrmannUNKNOWN Study Alliance Leukaemia (SAL)
Oct 19, 2012·The New England Journal of Medicine·Claudio AnasettiUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M Stone
Feb 27, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan K BurnettNigel Russell
May 2, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·James M ForanDaniel J Weisdorf
Nov 25, 2014·Haematologica·Richard F Schlenk

❮ Previous
Next ❯

Citations

Jan 29, 2018·International Journal of Hematology·Akiyoshi Takami
Oct 16, 2019·International Journal of Hematology·Masamitsu YanadaShingo Yano
Jan 13, 2018·Current Opinion in Hematology·Chezi Ganzel, Jacob M Rowe
Sep 22, 2018·Cancers·Beatrice U MuellerThomas Pabst
Sep 4, 2016·Journal of Hematology & Oncology·Francesco SaraceniUNKNOWN Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.